RHEUMATOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Anemia is common in elderly patients with rheumatoid arthritis (RA). This study aimed to evaluate the current status and influencing factors of anemia in RA patients, to provide insights for clinical RA treatment and care.

Material and methods:
This study included elderly patients with high RA activity treated in our hospital from June 1, 2021 to December 31, 2022 for analysis. The characteristics of RA patients were analyzed. Pearson correlation and logistic regression analysis were conducted to analyze the influencing factors of anemia in elderly patients with RA.

Results:
A total of 285 RA patients were included. The incidence of anemia in high RA activity patients was 62.46%. There were significant differences in the course of RA, hemoglobin (Hb), low density lipoprotein cholesterol (LDL-C), platelet/lymphocyte rate (PLR) and albumin (Alb) between RA patients with anemia and without anemia (all p < 0.05). Pearson correlation analysis indicated that course of RA (r = 0.522), Hb (r = 0.797), LDL-C (r = 0.558), PLR (r = 0.615) and Alb (r = 0.604) were correlated with anemia in patients with high RA activity (all p < 0.05). Logistic regression analysis indicated that course of RA ≥ 8 years (OR = 2.584, 95% CI: 1.822–3.647), LDL-C ≤ 2.8 mmol/l (OR = 3.202, 95% CI: 2.804–3.431), PLR ≥ 8 (OR = 2.183, 95% CI: 1.744–2.457), Alb ≤ 35 g/l (OR = 1.716, 95% CI: 1.401–2.006) were the risk factors of anemia in elderly patients with high RA activity (all p < 0.05).

Conclusions:
Anemia in elderly patients with high RA activity is closely related to the course of RA, LDL-C, PLR and Alb. Close attention should be paid to the monitoring of those indicators to take early intervention measures to improve the prognosis of RA patients.

 
REFERENCES (41)
1.
Prasad P, Verma S, Surbhi, et al. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 2023; 478: 69-88.
 
2.
Russell O, Lester S, Black RJ, Hill CL. Socioeconomic status and medication use in rheumatoid arthritis: a scoping review. Arthritis Care Res (Hoboken) 2023; 75: 92-100.
 
3.
Batko B, Korkosz M, już A, Wiland P. Management of rheumatoid arthritis in Poland – where daily practice might not always meet evidence-based guidelines. Arch Med Sci 2019; 17: 1286-93.
 
4.
Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 2021; 41: 863-77.
 
5.
Almutairi KB, Nossent JC, Preen DB, et al. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol 2021; 48: 669-76.
 
6.
Rong C, Yuan Z, Xiaoqi H. Epidemiological study on knee osteoarthritis among middle-aged and elderly people in Xujiahui Street, Xuhui District, Shangha. Shanghai Med 2021; 16: 11-5.
 
7.
Mengting S, Zhenjie W, Peixia G. Progress in diagnosis and treatment of senile onset rheumatoid arthritis. Chin General Med 2021; 19: 6-9.
 
8.
Zou W, Fang Y, Xu D, Zhu Y. Increasing global burden of rheumatoid arthritis: an epidemiological analysis from 1990 to 2019. Arch Med Sci 2023; 19: 1037-48.
 
9.
Jiayi Z, Na R, Zhen L. Analysis of screening results of rheumatoid arthritis among residents in Zhengzhou. Prev Med South China 2021; 26: 47-9.
 
10.
Yi H, Yaoyu L, Yulong L. Analysis of epidemiological characteristics of rheumatoid arthritis among residents in southern Guizhou from 2015 to 2018. Modern Prev Med 2019; 46: 4-7.
 
11.
Tai S, Lei W, Yachun L. Analysis of related factors of anemia in patients with rheumatoid arthritis. Chin J Geriatr 2021; 40: 5-8.
 
12.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
 
13.
Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011; 84: 1245-52.
 
14.
Smolen JS. Insights into the treatment of rheumatoid arthritis: a paradigm in medicine. J Autoimmun 2020; 110: 102425.
 
15.
Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A: 50S-7S.
 
16.
Sun Y, Liu J, Xin L, et al. Factors influencing the Sharp score of 1057 patients with rheumatoid arthritis and anemia: a retrospective study. J Int Med Res 2022; 50: 3000605221088560.
 
17.
Xiaoli Z, Pingping Q, Jing P. Efficacy of Yiqi Weixue capsule in the treatment of anemia patients with rheumatoid arthritis. Chin Prescription Drugs 2021; 19: 3-6.
 
18.
Bing L, Jianrui L, Jingbo S. Comparison of Xinfeng capsule and Tripterygium wilfordii polyglycosides tablets in the treatment of anemia in patients with rheumatoid arthritis. Chin Foreign Med Res 2022; 20: 4-6.
 
19.
Padula AS, Pappas DA, Fiore S, et al. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis Res Ther 2022; 24: 276.
 
20.
Gunther F, Straub RH, Hartung W, et al. Usefulness of soluble transferrin receptor in the diagnosis of iron deficiency anemia in rheumatoid arthritis patients in clinical practice. Int J Rheumatol 2022; 2022: 7067262.
 
21.
Uslu AU, Kucuk A, Sahin A, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis 2015; 18: 731-5.
 
22.
Sargin G, Senturk T, Yavasoglu I, Kose R. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab. Int J Rheum Dis 2018; 21: 2122-7.
 
23.
Enginar AU, Kacar C. Neutrophil-lymphocyte and platelet-lymphocyte rate and their seasonal differences in ankylosing spondylitis and rheumatoid arthritis patients using anti-TNF medication. Bratisl Lek Listy 2019; 120: 586-92.
 
24.
Sag S, Sag MS, Tekeoglu I, et al. Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis. J Back Musculoskelet Rehabil 2018; 31: 703-7.
 
25.
Qiu, C, Zhao X, She L, et al. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis 2019; 18: 54.
 
26.
Pierini FS, Botta E, Soriano ER, et al. Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study. Rheumatol Ther 2021; 8: 803-15.
 
27.
VanEvery H, Yang W, Su J, et al. Low-density lipoprotein cholesterol and the risk of rheumatoid arthritis: a prospective study in a Chinese cohort. Nutrients 2022; 14; 1240.
 
28.
Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol 2006; 33: 1766-9.
 
29.
Garcia-Chagollan M, Haernandez-Martinez SE, Rojas-Romero AE, et al. Metabolic syndrome in rheumatoid arthritis patients: relationship among its clinical components. J Clin Lab Anal 2021; 35: e23666.
 
30.
Dessie G. Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa. PLoS One 2022; 17: e0269431.
 
31.
Robertson J, Porter S, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis 2017; 76: 1949-52.
 
32.
An J, Alemao E, Reynolds K, et al. Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis. J Rheumatol 2016; 43: 1989-96.
 
33.
Akhmedov A, Crucet M, Simic B, et al. TNFalpha induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFalpha antibodies. Cardiovasc Res 2022; 118: 254-66.
 
34.
Tsuji H, Hashimoto M, Harada T, et al. Persistent anemia and hypoalbuminemia in rheumatoid arthritis patients with low serum triiodothyronine level. Mod Rheumatol 2020; 30: 640-7.
 
35.
Zhou Q, et al. Correlation between traditional Chinese medicine and reduced risk of readmission in rheumatoid arthritis patients with hypoproteinemia:a retrospective cohort study. Zhongguo Zhong Yao Za Zhi 2023; 48: 2241-8.
 
36.
Xiuli X, Jian L, Changjian S. Changes and correlation of protein metabolism in active rheumatoid arthritis. Chin J Clin Health 2010; 19: 11-4.
 
37.
Shan L, Meiling X, Jinghui C. Changes and significance of serum prealbumin in elderly patients with rheumatoid arthritis before and after treatment. Chin J Gerontol 2013; 33: 1-3.
 
38.
Qianqian P, Hongqin Y. The value of C-reactive protein/albumin in the diagnosis of disease activity of rheumatoid arthritis. Chin J Health Inspect 2022; 14: 32-6.
 
39.
Kishimoto T, Kang S. IL-6 revisited: from rheumatoid arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol 2022; 26: 323-48.
 
40.
Yong C, Fangfang Z, Xiaofeng Z. Correlation between albumin/globulin and DAS28 and ESR in patients with rheumatoid arthritis. J Jinan Univ 2019; 5: 40-1.
 
41.
Hefton A, Liang SY, Ni K, et al. Autoantibodies against citrullinated serum albumin in patients with rheumatoid arthritis. J Transl Autoimmun 2019; 2: 100023.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top